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Abstract
Background—Data collected as part of routine clinical practice could be used to detect 
cardiovascular outcomes in pragmatic clinical trials, or in clinical registry studies. The reliability 
of claims data for documenting outcomes is unknown.
Methods and Results—We linked records of Women's Health Initiative (WHI) participants 
aged 65 years and older to Medicare claims data, and compared hospitalizations that had diagnosis 
codes for acute myocardial infarction (MI) or coronary revascularization with WHI outcomes 
adjudicated by study physicians. We then compared the hazard ratios for active versus placebo 
hormone therapy based solely on WHI adjudicated events with corresponding hazard ratios based 
solely on claims data for the same hormone trial participants.
Agreement between WHI adjudicated outcomes and Medicare claims was good for the diagnosis 
for MI (kappa = 0.71 to 0.74), and excellent for coronary revascularization (kappa=0.88 to 0.91). 
The hormone:placebo hazard ratio for clinical MI was 1.31 (95% confidence interval (CI) 1.03 to 
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1.67) based on WHI outcomes, and 1.29 (CI 1.00 to 1.68) based on Medicare data. The hazard 
ratio for coronary revascularization was 1.09 (CI 0.88 to 1.35) based on WHI outcomes and 1.10 
(CI 0.89 to 1.35) based on Medicare data. The differences between hazard ratios derived from 
WHI and Medicare data were not significant in 1,000 bootstrap replications.
Conclusion—Medicare claims may provide useful data on coronary heart disease outcomes 
among patients aged 65 years and older in clinical research studies.
Clinical Trials Registration Information—www.clinicaltrials.gov, Trial Number 
NCT00000611
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Randomized clinical trials (RCTs) are the reference standard for clinical research studies, 
but are expensive and challenging to conduct. Methods to improve the efficiency of RCTs, 
while maintaining their validity, are therefore of considerable interest. A potential way to 
streamline RCTs would be to capitalize on electronic databases of health insurers or 
integrated health care systems to capture data about clinical events among trial participants. 
Medicare, for instance, provides health insurance coverage for Americans aged 65 years and 
older, as well as younger individuals with disability or end-stage renal disease, and collects 
electronic data on hospitalizations, outpatient visits, and other health care utilization for 
billing purposes. Medicare claims data are commonly used for health services research 
studies, and have increasingly been linked to clinical registries to obtain follow-up data 
(1-4). In contrast, claims data have been infrequently linked to RCTs (5-7), which usually 
include prospective follow-up and validation of endpoints. As such, the potential value of 
using claims data to document clinical outcomes in RCTs has been largely unexplored; if 
such an approach were feasible, it might simplify and improve the efficiency of RCTs.
The Women's Health Initiative (WHI) included two RCTs of hormone therapy (one using 
combination estrogen plus progestin [E+P] versus placebo, and the other using estrogen 
alone [E-only] versus placebo), with baseline enrollment between 1993 and 1998 and 
ongoing post-intervention follow-up (8, 9), as well as a dietary modification trial and an 
observational study. Data from WHI have been linked to Medicare files from the Centers for 
Medicare & Medicaid Services (CMS), expanding the data available on WHI participants. 
The purpose of the current study was to compare major coronary disease outcomes 
ascertained from Medicare files with physician adjudicated outcomes in the WHI hormone 
therapy trials.
Methods
The nationwide study population for these analyses consisted of women aged 65 years and 
older at study entry who were continuously enrolled in traditional fee-for-service Medicare 
Part A coverage. WHI participants were linked with CMS data using social security number, 
date of birth and, in some cases, date of death or residential zip code.
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The primary outcome for this analysis was incident acute MI, and the secondary outcome 
was coronary revascularization. We identified outcomes In the CMS Medicare Provider 
Analysis and Review data by using the International Classification of Diseases (9th 
Revision, Clinical Modification [ICD-9-CM]) principal diagnosis code, secondary diagnoses 
codes (up to nine), and the procedure codes of hospital discharges. We defined acute MI in 
the CMS data as hospitalizations with ICD-9-CM discharge diagnosis codes of 410.×0 or 
410.×1, and coronary revascularization by an ICD-9-CM procedure code for coronary artery 
bypass graft surgery (36.1×, 36.2) or percutaneous coronary intervention (00.66, 36.0, 36.00, 
36.01, 36.02, 36.05, 36.06, or 36.07). In the WHI, diagnoses of MI and coronary 
revascularization were established by physician adjudicators based on review of medical 
records using standardized forms and definitions (10, 11). Diagnosis of an acute MI was 
based on chart review findings of three standard factors: chest pain, diagnostic or suggestive 
ECG changes, and abnormal cardiac markers. We excluded the few (3%) silent, ECG-only 
MIs found in WHI clinical trial participants, as these events were, by definition, clinically 
unrecognized and would not be expected to appear in the CMS hospital data. Results were 
essentially unchanged when ECG-only MIs were included (Online Appendix).
We compared the agreement between outcomes identified in the CMS data and WHI 
adjudicated outcomes through December 31, 2007, the last date for which CMS data were 
available. We examined only first occurrences of these events, because WHI did not 
adjudicate recurrent events. Women were censored when they no longer had Medicare fee-
for-service coverage, or if they were lost to follow-up in WHI.
Agreement beyond chance between WHI and CMS data was evaluated with a kappa 
statistic.
First-Stage Analysis
To determine the optimal definition for an acute MI in the CMS data, we conducted a first 
stage analysis among women who were enrolled in the WHI observational study or the diet 
trial and were not participants in the hormone therapy trials. In a second stage analysis, we 
applied the operational definition of acute MI developed in the first stage to the independent 
sample of women in the two WHI hormone therapy trials (i.e., E+P and E-only).
Intention-to-Treat Analysis
Using the WHI hormone trial participants, we performed an intention-to-treat analysis based 
solely on Medicare determined outcomes among women 65 years of age and older, and 
calculated the hormone:placebo hazard ratios using Cox proportional hazards models. In 
order to maximize the number of events and narrow the confidence intervals for the hazard 
ratios, the primary analysis combined data from both hormone trials. We compared the 
incidence of MI among the women allocated randomly to hormone therapy or placebo 
during the period of active intervention, namely through July 7, 2002 in the E+P trial (8), 
and through February 29, 2004 in the E-only trial (9). Participants were censored when they 
were no longer enrolled in fee-for-service Medicare Part A.
We then compared the hazard ratios from the Medicare-based intention-to-treat analysis 
with the corresponding risk ratios derived from WHI adjudicated outcomes. To determine if 
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these hazard ratios differed significantly, we calculated the confidence interval around the 
difference between these two point estimates using the bootstrap technique (1000 
resamplings, with recomputation of the difference between the two hazard ratios in each 
bootstrap sample).
All participants gave written informed consent to participate in the WHI. The linkage of 
WHI and CMS data was approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center, which granted a waiver of additional consent for the linkage study.
Results
Agreement of MI Diagnosis
The WHI observational study and diet trial included 58,793 women aged 65 years and older 
nationwide at the time of study entry, 215 of whom were not followed for outcomes in WHI; 
52,735 of the remaining women (90%) were successfully linked to CMS records. The study 
population for the first stage analysis consisted of 37,397 women aged 65 years and older at 
entry who had traditional fee-for-service Medicare coverage at WHI enrollment. In this 
population, 1,345 women had a clinically evident MI adjudicated by WHI, 1,195 had a 
hospitalization with a principal diagnosis of acute MI in the CMS data and an additional 306 
women had a hospitalization with a secondary diagnosis code for an acute MI in the CMS 
data.
The agreement between WHI and CMS diagnoses of acute MI was good (kappa 0.71, 
p<0.0001). A total of 914 women had an MI in both data sets, with exact agreement on the 
date of the event in 82%, and agreement within 30 days in 94% (Table 1). However, 281 
women with an MI in the CMS data did not have an MI in the WHI data, and 431 women 
with an MI in the WHI data did not have an MI in the CMS data (Table 1).
There were several reasons for disagreement between the WHI and CMS data sources for an 
acute MI. Almost half of the women with an MI in the CMS data but not in the WHI data 
had not reported a hospitalization to the WHI staff, and an additional 12% reported a 
possible clinical event that was not adjudicated, either because the WHI staff could not 
obtain sufficient hospital records, or because the reported reason for admission did not meet 
WHI criteria for adjudication. In most of the remaining cases, another cardiovascular 
outcome was adjudicated by WHI after review of records. Restricting the analyses to those 
cases with adequate documentation would improve the kappa to 0.76 for the diagnosis of MI 
(Supplemental Material, Supplemental Table 1).
Among the 431 women who had a WHI adjudicated MI but no hospitalization with a 
principal diagnosis of MI in the CMS data, 32% had a secondary diagnosis of an acute MI, 
many of which were adjudicated by WHI as a procedure-related MI. (Only 3.7% of 
admissions with a principal diagnosis of MI in the CMS data were adjudicated as procedure-
related MIs.) Most of the remaining women (39%) were hospitalized with another principal 
cardiovascular diagnosis, 15% had a non-cardiovascular principal diagnosis, and 14% had 
no CMS record of a hospital admission within 30 days of the date of MI recorded by WHI.
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Based on the reasons for disagreement between CMS and WHI diagnoses, we examined an 
alternative definition of MI in CMS data that included either a principal or secondary 
diagnosis of acute MI, which we compared with the WHI diagnosis of clinically evident MI 
(Table 1). This definition modestly improved the agreement between the two data sources, 
with a kappa of 0.74 (p<0.0001). The kappa statistic for agreement between a WHI 
diagnosis of non-procedure related MI and a CMS primary diagnosis of acute MI was 0.73 
(Table 1). Based on these results, we decided a priori that the second stage analysis would 
compare the WHI diagnosis of clinical MI with a CMS principal or secondary diagnosis of 
acute MI, and compare the WHI diagnosis of non-procedure-related MI with a CMS 
principal diagnosis of acute MI.
Agreement between CMS data and WHI data was quite high for coronary revascularization 
procedures, with a kappa statistic of 0.91 for coronary artery bypass graft surgery, and a 
kappa of 0.88 for percutaneous coronary intervention (Table 1).
Intention-to-Treat Analysis
In the WHI, 10,739 women were randomized in the E-only trial and an additional 16,608 
women were randomized in the E+P trial. At the time of study entry, 12,705 hormone trial 
participants were aged 65 years or older, and 11,963 (94%) were linked successfully to CMS 
records. The baseline clinical characteristics of the 8,375 women with Medicare fee-for-
service coverage at study entry were generally similar to those of the remaining women aged 
65 and over, but the women with fee-for-service coverage were slightly younger and less 
likely to have had prior hormone therapy (Table 2).
Over a mean follow-up of 73.9 months, 270 women with fee-for-service Medicare coverage 
in the combined hormone trial populations had a clinically evident MI adjudicated by the 
WHI; in comparison, 228 women had a hospitalization documented in Medicare data with a 
principal or secondary diagnosis of acute MI over a mean follow-up of 65.2 months. In the 
intention-to-treat analysis of the combined trials, the hazard ratio of 1.29 for hormone 
therapy compared with placebo based on a CMS principal or secondary diagnosis of MI 
agreed well with the hazard ratio of 1.31 based on WHI adjudicated clinical MI (Figure 1). 
The difference of 0.02 between these hazard ratios had 95% confidence limits of -0.22 to 
+0.25 based on 1,000 bootstrap replications. Comparing the more restrictive definition of 
non-procedure related MI in the WHI data with a principal diagnosis of acute MI in the 
CMS data, the hazard ratio of 1.38 based on CMS data also agreed well with the hazard ratio 
of 1.28 based on WHI adjudicated outcomes (Figure 1). The confidence limits on the 
difference of -0.10 between these hazard ratios ranged from -0.40 to +0.18. Intention-to-treat 
comparisons in the E+P trial and E-alone trial are presented separately in the Supplemental 
Material, Supplemental Table 5.
A total of 352 women had a coronary revascularization procedure adjudicated by WHI, 
compared with 374 women with a procedure recorded in the CMS data (Table 2). In the 
intention-to-treat comparison using coronary revascularization as an outcome, the hazard 
ratio for hormone therapy of 1.10 based on CMS data agreed well with the hazard ratio of 
1.09 based on WHI data (Figure 1). The confidence limits on the -0.01 difference in these 
hazard ratios ranged from -0.16 to +0.15.
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This study demonstrates that administrative data may be reliable and useful in assessing 
coronary heart disease outcomes among patients aged 65 years and older in clinical research 
studies. Furthermore, our data suggest that treatment comparisons based on outcomes 
ascertained in CMS claims yield hazard ratios similar to those determined by standard 
clinical trial outcome ascertainment and adjudication procedures. The use of claims data to 
detect outcomes may be particularly attractive in conducting large “pragmatic” clinical trials 
that assess the comparative effectiveness of alternative treatments, and in extending follow-
up of trial participants.
In this study, the agreement was quite good between WHI adjudicated outcomes and 
hospitalized events documented in CMS data (Table 1). Many of the instances of 
“disagreement” between the two data sources arose from a lack of hospital records needed 
for outcome adjudication. As such, the kappa statistics would have been higher (0.76 for 
acute MI) had we analyzed only events with adequate documentation (Supplemental 
Material, Supplemental Table1). The level of agreement between WHI adjudicated 
outcomes and CMS determined events in this study was close to the level of agreement 
between WHI local and central adjudicators who reviewed the same cases: kappa statistics 
were 0.80 for acute MI, 0.94 for coronary bypass surgery, and 0.89 for percutaneous 
coronary intervention (11).
Since some disagreement is expected whenever two different methods are used to document 
outcomes in a clinical trial, the key question is whether the comparative effectiveness of 
randomized treatments is similar based on outcomes identified by the alternative 
approaches. In this study, we found the hazard ratios for hormone therapy relative to placebo 
were quite similar whether they were based on the WHI adjudicated events or the CMS 
documented outcomes. The bootstrap confidence limits around the difference in hazard 
ratios included zero, suggesting there was no significant bias in the estimated treatment 
effect based on CMS data.
In previous studies, a discharge diagnosis of acute MI in administrative data has generally 
been confirmed by review of hospital records. Burwen and associates confirmed the 
principal diagnosis of acute MI in 87% of 270,467 hospital discharges in Medicare data 
nationwide (12). Yeh and coworkers found 97% of hospitalizations in Kaiser Permanente of 
Northern California with a primary discharge diagnosis of acute MI met standard diagnostic 
criteria for MI (13). Kiyota and coworkers confirmed on record review 94% of 1,851 
admissions in Pennsylvania with a principal or first-listed secondary diagnosis of acute MI 
(14). In the Atherosclerosis Risk in Communities Study, 75% of 17,900 discharges with a 
410.xx discharge code in any position (principal or secondary) had a definite or probable MI 
upon record review, 12% had a suspected MI, and 13% had no MI (15). The literature 
therefore supports a discharge diagnosis of acute MI as having high positive predictive 
value, consistent with the findings in this study.
While a discharge diagnosis of acute MI has high positive predictive value, not all MIs will 
be detected using claims data. An acute MI that was a consequence of a procedure or 
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medical illness was less frequently coded in Medicare claims. In the WHI, an acute MI was 
actively sought and found by WHI adjudicators in some records that lacked either an ICD-9 
code for acute MI, or a participant self-report of an MI, or both (11). Consequently, some 
acute MIs would be missed if administrative claims were the only source of data. 
Conversely, in this study the CMS data captured some acute MIs that were not identified by 
the standard WHI outcome surveillance procedures. Similar to other clinical trials, outcomes 
ascertainment in WHI was based on contacts by study personnel with the participant or her 
family. Although complete loss to follow-up was uncommon in WHI, participants who had a 
recent illness may have been less likely to respond to attempts to contact them, and medical 
records may not have been released. Respondents' recall of possible outcome events is also 
imperfect, so ascertainment of outcomes may be incomplete. Hospital claims do not depend 
on the recall of the participant or family, and hence provide an independent method of 
identifying potential clinical outcome events. Silent, ECG-only MIs would not be detected 
in claims, since they do not result in a hospital admission; but only 3% of MIs in WHI were 
detected by ECG only, and our results were essentially unchanged when they were included 
in the analysis (Supplemental Material, Supplemental Table 1).
Depending on the type of event, claims data alone may be sufficiently accurate for purposes 
of the clinical trial. Hospital discharge codes in this study were quite accurate, for instance, 
in identifying coronary revascularization procedures, particularly coronary bypass surgery. 
Arguably, trials might not need to investigate such events further, and could accept 
discharge codes as adequate documentation. The recent trend towards performing 
percutaneous coronary interventions in the outpatient setting would, however, require use of 
Part B codes to identify all procedures. The ICD-9CM codes might be used to identify other 
clinical events, or to document health care utilization and cost. Claims data would not, 
however, be useful in early phase studies of new therapies, since clinical records of 
suspected outcome events are important for regulatory review. Nor would claims data be 
useful in assessing MIs after initial treatment for acute coronary syndrome, since the timing 
of these events requires careful review of serial cardiac markers and ECGs (16, 17). Claims 
data could be very useful, however, for long-term follow-up in pragmatic clinical trials (or 
registry studies) of approved therapies.
In WHI, acute MI was one component of the composite coronary heart disease (CHD) 
endpoint, which consisted of CHD death, non-fatal MI, and silent MI. We did not attempt to 
assess the broader outcome of CHD death in this study, but focused on the more specific 
outcome of acute MI. While most CHD deaths would be expected to have had a preceding 
hospitalization for an acute MI or a coronary revascularization procedure, some deaths due 
to coronary disease occur out of hospital, or have hospital diagnosis codes other than MI. 
Algorithms to identify CHD deaths accurately from claims data and death records are 
needed.
Most of the women aged 65 years and older in the WHI hormone trials were linked 
successfully to the CMS database, but only 69% had traditional fee-for-service Medicare 
coverage, with complete billing data to document their subsequent hospitalizations. CMS 
data, as currently collected, would provide outcome data for most, but not all, of the 
participants aged 65 and older in a clinical trial. Supplementing CMS data with the 
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administrative records of integrated health care systems in the United States (e.g., health 
maintenance organizations or the Department of Veteran Affairs), or using universal health 
insurance plans in other countries, would provide data for a larger proportion of participants 
in a clinical trial, and thus might be able to document most clinical outcomes based on data 
collected as part of the routine delivery of care. Another practical limitation of using claims 
to assess outcomes is that CMS data are available only after some delay. Traditional event 
identification and adjudication also take time, however, so that it is difficult to assess the 
degree of delay that would be added by relying on claims data.
While women aged 65 years and older differed in many baseline characteristics from 
younger women, there were relatively minor differences between older women with or 
without fee-for-service Medicare coverage (Table 2). In a previous study of the National 
Health and Nutrition Examination participants aged 65 years and older, the clinical 
characteristics of 1,472 Medicare fee-for-service were quite similar to those of the 603 
Medicare Advantage enrollees (18). The present study included four times as many 
participants, so our findings confirm and extend their results. Nevertheless, Medicare fee-
for-service beneficiaries may differ in other ways from Medicare Advantage participants, 
and so may not be fully representative of the entire population aged 65 and older.
In summary, this study suggests that Medicare claims data can provide useful data about 
coronary disease outcomes of older participants in a clinical research study, even though not 
all participants can be followed using these data. The linkage of administrative data with 
clinical trial (or registry) databases should be evaluated further, as it has the potential to 
extend the length of follow-up, expand the range of outcomes studied, and identify outcomes 
that might otherwise be unobtainable.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Outcomes Among Women Aged ≥65 Years Assigned Randomly to Hormone Therapy 
or to Placebo, According to Source of Outcome Data
CMS = Center for Medicare and Medicaid Services
MI = Myocardial infarction
WHI = Women's Health Initiative
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Table 2
Baseline Clinical Characteristics of Women ≥65 Years of Age at Entry in WHI Hormone 
Therapy Trials *
Medicare FFS (n=8375) Not Medicare FFS (n=3588)
Age 69.8 ± 3.8 70.1 ± 3.9
Years since menopause 21.5 ± 7.5 22.0 ± 7.7
Prior hormone therapy 2626 (31%) 1326 (37%)
E-only trial 3375 (40%) 1425 (40%)
E+P trial 5000 (60%) 2163 (60%)
Diabetes (treated) 506 (6%) 237 (7%)
Hypertension (treated) 2322 (30%) 1027 (30%)
Hypercholesterolemia (treated) 1293 (17%) 625 (17%)
Ever smoked 3815 (46%) 1706 (48%)
Body mass index
 <25 kg/m2 2441 (29%) 1037 (29%)
 25 to <30/Kg/m2 3066 (37%) 1290 (36%)
 >=30 kg/m2 2822 (34%) 1248 (35%)
*
Excludes 742 women not matched to data from the Centers for Medicare & Medicaid Services
E = Estrogen
E+P = Estrogen plus progestin
FFS = Fee-for-service
WHI = Women's Health Initiative
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